Cremophor EL (CrEL) is commonly used to solubilize paclitaxel (Ptx); a widely 35 established anticancer agent used against many types of cancer. Using laser-based 36 microplate nephelometry, in this work we assessed the precipitation kinetics of Ptx in 37 CrEL-containing formulations upon dilutions with different infusion media or upon 38 introduction into rat plasma. The precipitation profile of Ptx was assessed for a Taxol-like 39 formulation and compared with an preparation with reduced CrEL content. These two 40 formulations were diluted at various ratios in compatible infusion media and with or 41 without rat plasma. The percentages of Ptx precipitated in dilution media and protein-42 binding in plasma were quantified using HPLC. The findings of turbidity measurements 43 were in good agreement with HPLC. Despite the presence of albumin, it was possible to 44 assess turbidity within infusion solutions and predict Ptx precipitation. Upon addition to 45 plasma, no precipitation in Taxol-like formulation occurred after 2 hours. By contrast, 46 precipitation occurred immediately in CrEL-reduced formulation. It is possible that the 47 high percentage of protein-bound Ptx in plasma (98.5%-99.2%) has inhibited drug 48 precipitation. Turbidity measurements using laser nephelometry can provide a rapid 49 screening tool when developing intravenous formulations for poorly soluble drugs, such 50 as Ptx and assess its stability upon dilution in animal plasma. 51 52 53 54 Paclitaxel (Ptx) is a widely used antineoplastic taxane with established activity against a wide 55 range of cancers. Ptx was approved by FDA in 1992 for the treatment of ovarian cancer 1, 2 . The 56 use of Ptx has extended thereafter to include lung cancer 3 , AIDS related Kaposi's sarcoma 4 and 57 urologic, colon and head and neck cancers as well as other solid tumors 5 . However, Ptx is limited 58 by its poor aqueous solubility (<0.01 mg/ml) 6, 7 . Ptx is commercially available in the market under 59 the brand name of Taxol ® which is an intravenous solution of Ptx in a solvent mixture of 60 Cremophor EL (CrEL; ethoxylated castor oil) and dehydrated ethanol (1:1 v/v). The formulation 61 is usually diluted by 5-20 times using isotonic solutions such as sodium chloride (0.9%) or dextrose 62 (5%) prior to administration via intravenous infusion 8, 9 . 63 64
Introduction 4 22 . Thus, the potential application of laser nephelometry in evaluating the precipitation kinetics of 85 poorly soluble drugs in physiologically relevant media such as plasma merits to be explored. 86 87 In this study, we have investigated the feasibility of laser nephelometry as a rapid screening tool 88 to investigate the precipitation kinetics of Ptx in CrEL-based formulations using different infusion 89 media as well as blood plasma. In order to gain further insight into the effect of CrEL on Ptx 90 precipitation, we have compared the therapeutic doses of a Taxol-like formulation with an in-house 91 formulation that contained a reduced content of CrEL. Taxol-like formulations were prepared by dissolving Ptx in CrEL and ethanol (1:1 v/v) to 103 constitute a drug concentration of 6 mg/ml. The same concentration of Ptx was prepared with 104 reduced proportion of CrEL (CrEL and ethanol; 1: 9 v/v) or in complete absence of CrEL (i.e. 105 using only ethanol). To mimic the concentrations commonly used for intravenous administration 106 of Ptx, the drug solutions were diluted to 1.2, 0.6, 0.4, or 0.3 mg/ml using two infusion media, 107 namely NaCl (0.9%) or dextrose (5%). Other samples of drug solution were diluted with deionized 108 water which was used as control medium for comparing the precipitation behavior of the drug.
109

Scanning electron microscopy (SEM)
110
SEM imaging was utilized for assessing the habit and aggregation behavior of Ptx crystals as a 111 result of 1:4 dilution with NaCl solution, dextrose solution or deionized water (18 hours after 112 dilution). This was performed by centrifugation of the samples for 10 min followed by freeze-113 drying (Edwards Micro Modulyo freeze-dryer, IL, USA) of the sediment in order to completely 114 remove water from the samples prior to SEM imaging. The Ptx specimens were then gold-coated 115 5 using a sputtering technique for 2 min using a JFC-1200 Fine Coater (JEOL, Tokyo, Japan). The 116 crystals were viewed under SEM (JSM-6301F, JEOL) and images were taken at 3 kV. In case of 117 Ptx crystals in dextrose, the samples were washed three times with an extra volume of distilled 118 water and centrifuged for 5 min at 15 G before taking the images. This extra step was done to wash 119 out the sugar deposited on the surface of the crystals, hence observation of the crystal habit is (1:9 v/v), and Ptx samples in the solvent system were diluted with 50 ml deionized water within 126 the dispersion cell. Crystal size and size distribution were respectively expressed as volume 127 median diameter (VMD; 50% undersize) and span. Span = (90% undersize -10% undersize) 128 /VMD. Laser diffraction was used to accurately measure the size of Ptx crystals that are expected 129 to have VMD values higher than 1 μm after 2, 4, 8, and 18 h of dilution. Measurements of this 130 analysis were conducted in triplicate using three different batches with 10 min run for two times. In order to assess Ptx concentration in Wistar rat plasma, the serum was separated via 153 centrifugation at 2,000G for 4 h. After preparing methanolic solutions of Ptx at different 154 concentrations (200-10,000 ng/ml), the solvent was evaporated (150 µL in 300 µL capacity HPLC 155 vial with built-in inserts, Fisher Scientific, UK) at 40˚C for 45 min using a vacuum oven. The 156 solutions were reconstituted with the same volume of serum which was added and mixed for 2 min 157 using a vortex mixer. All samples were incubated at 37˚C for 2 h under continuous shaking 158 followed by HPLC analysis. The Limit of Quantification (LOQ) of Ptx (based on peak-to-noise 159 ratio >10) was defined as 2,500 ng/ml in mobile phase and 2,000 ng/ml in serum. The linearity 160 was 0.999 in the range of 20-10,000 ng/ml and reproducibility was 0.66%.
162
Turbidity studies in infusion media and plasma using laser nephelometry 163 Taxol-like and formulations with reduced CrEL proportion were independently diluted at 1:4, 1:9, 164 1:14 and 1:19 ratios in each medium separately (dextrose 5% w/v, NaCl 0.9% w/v or deionized 165 water). Wistar rat plasma (100 µl) was accurately placed into the 96-well plate with an equivalent 166 volume of each one of the three media (blank samples). The pipetting of the samples was 167 performed quickly and instantly subjected to nephelometric analysis at 37˚C with 61 cycles, a gain 168 of 74 and a laser beam focus of 2 mm. The samples (n=3) were subjected to orbital shaking of 2 169 mm width, which lasted 3 sec before each cycle. No animals were used in our studies, and all 170 animal plasma samples were purchased, as indicated in section 2.1.
172
Ptx protein binding studies 173 Four dilutions (1:4, 1:9, 1:14, and 1:19 v/v) were prepared with 5% w/v dextrose or 0.9% w/v 174 saline solutions. After adding equal amounts of plasma (150 µl) in each solution, the samples were 175 incubated with continuous shaking for 2 h at 37˚C followed by centrifugation in Centrifree ® 176 ultrafiltration tubes at 2,000 G for 3 h. The serum containing unbound drug was collected from 177 7 each sample and its volume was estimated by pipette measurement before conducting HPLC 178 analysis.
180
Statistical analysis 181 One-way ANOVA was employed using SPSS Software (22.0.0.2) to analyse the results.
182
Differences in results of p <0.05 were considered to be significant. can also be seen that Ptx diluted in infusion media had higher turbidity when using higher drug 216 concentrations (1:4). One possible explanation is that lower Ptx concentrations in infusion 217 solutions reduced the level of supersaturation and hence the rate of precipitation over 18 h was 218 further dropped compared to samples having higher Ptx concentrations. This is also reveals that if 219 the decision in formulation development was to reduce the content of CrEL, then dilution with 220 saline solution would be a better choice than using dextrose. (Figure 4) . The difference between HPLC and 229 nephelometry findings can be attributed to the increased turbidity which is linked to crystal growth 230 with time. In addition, there was limited precipitation of Ptx during the first 6 h for CrEL-reduced 231 formulation (CrEL: ethanol 1:9) ( Figure 5B ). It is possible that for this formulation, the 232 concentration of drug was reduced below its saturation limit, resulting in no drug precipitation. As 233 the formulation was diluted with the infusion medium, the concentration of the solvent system was 234 also reduced, resulting in a marked decrease in Ptx solubility and eventually supersaturation and Turbidity studies and protein binding in plasma 240 Precipitation of hydrophobic drugs has always been a concern during parenteral infusion of 241 formulations. In our investigation, Ptx was directly introduced to plasma after dilution. Our study 242 endeavored to mimic the injection conditions and to investigate the effect of plasma protein 243 binding on Ptx solubility. On the other hand, the addition of reduced CrEL formulation led to a significant increase in 262 turbidity for 1:4 dilutions when introduced to rats plasma (Figure 7) . However, such an effect is 263 less noticed in other dilutions particularly with dextrose solutions. Such an effect might be related 264 to albumin binding to Ptx. A very high percentage of protein-bound Ptx was measured in plasma 265 (98.5 to 99.2%) as shown in Figure 8 . Similarly, it has also been demonstrated that bound Ptx to 266 plasma proteins ranged from 76 to 97% using various animal species 24 . It is possible that protein 267 binding to Ptx has reduced the amount of free drug available for crystal formation. Table 1 The size of Ptx crystals in 5% (w/v) dextrose, 0.9% (w/v) NaCl and in deionized water 299 using laser nephelometry (n=3). (Dex) and 0.9% (w/v) NaCl at 1:4, 1:9, 1:14, and 1:19 infusion ratios (mean ± SD, n=3). 
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and 0.9% (w/v) NaCl at 1:4, 1:9, 1:14, and 1:19 infusion ratios (mean ± SD, n=3).
